US Eyes Psychedelics for Mental Health Revolution

WASHINGTON, April 18, 2026 — The U.S. government issued a directive on April 18, 2026, aimed at speeding the development and expanding the availability of psychedelic drugs for serious mental illnesses. Officials framed the move as a response to ongoing difficulties in treating conditions including major depressive disorder and substance abuse. The directive cited that these challenges affect over 14 million American adults.

The executive order instructs the Food and Drug Administration (FDA) to elevate its review of psychedelic drug applications that already hold Breakthrough Therapy designations. Under the order, the FDA is directed to use Commissioner’s National Priority Vouchers as part of that prioritization. The stated goal is to shorten timelines within existing regulatory processes for therapies that meet the specified criteria.

In parallel, the order tells the FDA and the Drug Enforcement Administration (DEA) to create a pathway allowing eligible patients to obtain these drugs under the Right to Try Act. The directive includes provisions for Schedule I handling authorizations for medical professionals, which would be required for the controlled-substance status referenced in the order. Officials said this is intended to clarify how access could occur while the substances remain subject to Schedule I controls.

On funding, the Department of Health and Human Services (HHS) is directed to allocate at least $50 million from existing funds through the Advanced Research Projects Agency for Health to support state-level programs that advance psychedelic drug research. The order describes this as a mechanism to expand research capacity and program activity at the state level, using already-available resources rather than newly appropriated funding.

The directive also calls for coordinated work among HHS, the FDA, and the Department of Veterans Affairs to increase clinical trial participation and improve data sharing. It further instructs the agencies to expand the generation of real-world evidence related to these treatments. Officials said these steps are designed to strengthen the evidence base used in evaluating safety and effectiveness.

Separately, the Attorney General is tasked with ensuring timely rescheduling of Schedule I substances that complete Phase 3 clinical trials for serious mental health disorders. The order links that rescheduling step to facilitating eventual approval, indicating that scheduling status is a key procedural factor in the pathway described.

Uncertainties remain around how quickly agencies will implement the new processes and how eligibility and operational requirements will be defined under the Right to Try pathway. The directive sets out responsibilities across multiple agencies, but it does not specify timelines in the text provided. Officials said the overall intent is to accelerate development and broaden access while maintaining the required regulatory steps.